#678137
Galar an chraicinn chnapánaigh
Lumpy skin disease
Scag na torthaí
Bailiúcháin
Foirmeacha na bhfocal
142 toradh in 19 doiciméad
#705103
Galar an chraicinn chnapánaigh
Lumpy skin disease
#1651590
Víreas ghalar an chraicinn chnapánaigh;
Lumpy skin disease virus;
#1752007
28.Víreas ghalar an chraicinn chnapánaigh;
28.Lumpy skin disease virus;
#2055484
Víreas ghalar an chraicinn chnapánaigh;
Lumpy skin disease virus;
#2087876
atá suite lasmuigh de limistéar inar deimhníodh ráig d’ionfhabhtú víreas ghalar an chraicinn chnapánaigh;
located outside an area where an outbreak of infection with LSDV has been confirmed;
#2087881
lena n-áirítear limistéar inar deimhníodh ráig d’ionfhabhtú víreas ghalar an chraicinn chnapánaigh;
which includes an area where an outbreak of infection with LSDV has been confirmed;
#2087886
BEARTA SPEISIALTA RIALAITHE GALAR IN AGHAIDH VÍREAS GHALAR AN CHRAICINN CHNAPÁNAIGH
SPECIAL DISEASE CONTROL MEASURES AGAINST INFECTION WITH LSDV
#2087888
Criosanna srianta agus vacsaíniú a bhunú in aghaidh víreas ghalar an chraicinn chnapánaigh
Establishment of restricted zones and vaccination against infection with LSDV
#2088097
RIALACHA MAIDIR LE PLEANANNA VACSAÍNITHE A BHAINEANN LE hIONFHABHTÚ VÍREAS GHALAR AN CHRAICINN CHNAPÁNAIGH
RULES FOR VACCINATION PLANS CONCERNING INFECTION WITH LUMPY SKIN DISEASE VIRUS
#2273227
Víreas ghalar an chraicinn chnapánaigh;
Lumpy skin disease virus;
#2297870
Ionfhabhtú ghalar an chraicinn chnapánaigh
Infection with lumpy skin disease virus
#2697028
Víreas ghalar an chraicinn chnapánaigh;
Lumpy skin disease virus;
#2720218
Iarscríbhinn IX maidir le vacsaíniú in aghaidh ionfhabhtú le galar an chraicinn chnapánaigh (LSD).
Annex IX on vaccination against infection with lumpy skin disease virus (LSD).
#2720450
Ionfhabhtú le galar an chraicinn chnapánaigh (LSD)
Infection with lumpy skin disease virus (LSD)
#2720529
TRÉIMHSÍ ATHSHLÁNAITHE LE HAGHAIDH VÍREAS GHALAR AN CHRAICINN CHNAPÁNAIGH TAR ÉIS VACSAÍNIÚ PRÓIFIOLACSACH ÉIGEANDÁLA
RECOVERY PERIODS FOR LSD FOLLOWING EMERGENCY PROTECTIVE VACCINATION
#2720530
An cineál faireachais chun easpa tarlaithe víreas ghalar an chraicinn chnapánaigh a léiriú
Type of surveillance to demonstrate the absence of occurrence of LSD
#2796075
Tháinig galar an chraicinn chnapánaigh chun cinn san Aontas den chéad uair in 2015 sa Ghréig.
LSD occurred in the Union for the first time in 2015 in Greece.
#2822142
Víreas ghalar an chraicinn chnapánaigh;
Lumpy skin disease virus;
#2795994
Is galar veicteoir-iompartha é galar an chraicinn chnapánaigh, arb é is cúis leis víreas ghalar an chraicinn chnapánaigh, galar a bhíonn ar bhó-ainmhithe agus is cúis le caillteanais eacnamaíocha nach beag, laghdú ar an tál bainne, cnaíteacht thromchúiseach, damáiste buan do sheithí, roinnt deacrachtaí tánaisteacha agus éineart ainsealach ar feadh míonna, agus toirmisc thrádála.
Infection with lumpy skin disease (LSD) virus, caused by lumpy skin disease virus (LSDV), is a vector-borne disease of bovine animals that causes substantial economic losses, reduces milk yield, causes severe emaciation, permanent damage to hides, several secondary complications, months-long chronic debility, and incurs trade bans.
#2087816
Is galar veicteoir-iompartha é ionfhabhtú víreas ghalar an chraicinn chnapánaigh, arb é is cúis leis víreas ghalar an chraicinn chnapánaigh, a bhíonn ar eallach agus ar bhuabhaill fhiáine Áiseacha, galar is féidir a bheith ina chúis le caillteanais shuntasacha eacnamaíocha, laghdú ar thoradh bainne, cnaíteacht thromchúiseach, damáiste buan do sheithí, deacrachtaí tánaisteacha éagsúla agus cothú éinirt ainsealaigh, agus tabhú toirmeasc gluaiseachta nó trádála.
Infection with lumpy skin disease virus, caused by the lumpy skin disease virus (LSDV), is a vector-borne disease of cattle and Asian water buffalo that can cause substantial economic losses, reduce milk yield, cause severe emaciation, permanent damage to hides, several secondary complications, chronic debility, and incur movement or trade bans.
#2087823
Roimhe sin, le Cinneadh Cur Chun Feidhme (AE) 2016/2008 ón gCoimisiún, leagadh síos rialacha maidir le bearta rialaithe sláinte ainmhithe i ndáil le hionfhabhtú víreas ghalar an chraicinn chnapánaigh sna Ballstáit nó i gcodanna díobh a liostaítear in Iarscríbhinn I a ghabhann leis, lena n-áirítear na híoscheanglais le haghaidh cláir vacsaínithe in aghaidh ionfhabhtú víreas ghalar an chraicinn chnapánaigh a chuireann na Ballstáit faoi bhráid an Choimisiúin lena bhformheas.
Previously, Commission Implementing Decision (EU) 2016/2008 laid down rules on animal health control measures in relation to infection with LSDV in the Member States or parts thereof listed in Annex I thereto, including the minimum requirements for vaccination programmes against infection with LSDV submitted by the Member States to the Commission for approval.
#2087831
Bunaithe ar an bhfaisnéis eipidéimeolaíoch atá ar fáil go dtí seo, ar thorthaí an fhaireachais ar ionfhabhtú víreas ghalar an chraicinn chnapánaigh agus ar vacsaíniú in aghaidh an ghalair sin, is iomchuí leanúint leis an vacsaíniú in aghaidh ionfhabhtú víreas ghalar an chraicinn chnapánaigh sna limistéir ardriosca sa Bhulgáir agus sa Ghréig, ar a laghad.
Based on the available epidemiological information to date, the results of surveillance for infection with LSDV and vaccination against that disease, it is appropriate that vaccination against infection with LSDV should at least continue in the high-risk areas of Bulgaria and Greece.
#2087833
De réir thuarascáil eolaíoch an Údaráis Eorpaigh um Shábháilteacht Bia (EFSA) maidir le hionfhabhtú víreas ghalar an chraicinn chnapánaigh, a formheasadh an 30 Eanáir 2020 (Tuarascáil EFSA), ba cheart vacsaín homalógach a úsáid chun go laghdófaí an riosca maidir le hionfhabhtú víreas ghalar an chraicinn chnapánaigh a leathadh a thuilleadh go dtí oirdheisceart na hEorpa.
According to the scientific report of the European Food Safety Authority (EFSA) on infection with LSDV, approved on 30 January 2020 (the EFSA Report), a homologous vaccine should be used to reduce the risk of the further spread of infection with LSDV to south-eastern Europe.
#2087839
Ina theannta sin, ba cheart go liostófaí sa Rialachán seo criosanna srianta na mBallstát atá i mbun pleananna vacsaínithe coisctheacha ina bhfuil vacsaíní maolaithe beo i gcás nach bhfuil aon ráig d’ionfhabhtú víreas ghalar an chraicinn chnapánaigh (crios srianta I); agus limistéir ina bhfuil ráigeanna d’ionfhabhtú víreas ghalar an chraicinn chnapánaigh (crios srianta II).
In addition, this Regulation should list the restricted zones of Member States carrying out preventive vaccination plans with live attenuated vaccines where there are no outbreaks of infection with LSDV(restricted zone I); and areas with outbreaks of infection with LSDV (restricted zone II).
#2796001
Aicmítear na criosanna sin mar chrios srianta I, lonnaithe lasmuigh de limistéar inar deimhníodh ráig d’ionfhabhtú le víreas ghalar an chraicinn chnapánaigh, agus crios srianta II, crios a chuimsíonn limistéar inar deimhníodh ráig d’ionfhabhtú le víreas ghalar an chraicinn chnapánaigh.
These zones are classified as restricted zone I, located outside an area where an outbreak of infection with LSDV has been confirmed, and restricted zone II, which includes an area where an outbreak of infection with LSDV has been confirmed.
#2796007
Le Rialachán Tarmligthe (AE) 2023/361 déantar foráil freisin maidir le tréimhsí athshlánaithe le haghaidh ghalar an chraicinn chnapánaigh, i ndiaidh vacsaíniú próifiolacsach éigeandála, ar tréimhsí idir 8 agus 26 mhí iad, de réir an chineál faireachais, an chrios vacsaínithe, agus an tráth a mharaítear an cás deiridh de ghalar an chraicinn chnapánaigh nó an tráth a rinneadh an vacsaíniú deiridh.
Delegated Regulation (EU) 2023/361 also provides for recovery periods for LSD, following emergency protective vaccination, that range between 8 and 26 months, depending on the type of surveillance, the vaccination zone, and the time of the slaughter or killing of the last LSD case and/or the time of the last vaccination.
#2087820
Ina theannta sin, liostaítear ionfhabhtú víreas ghalar an chraicinn chnapánaigh san Iarscríbhinn a ghabhann le Rialachán Cur Chun Feidhme (AE) 2018/1882 ón gCoimisiún mar ghalar i gcatagóir A, D agus E.
In addition, infection with LSDV is listed in the Annex to Commission Implementing Regulation (EU) 2018/1882 as a category A, D and E disease.
#2087810
lena leagtar síos bearta rialaithe speisialta ar feadh tréimhse theoranta a bhaineann le hionfhabhtú víreas ghalar an chraicinn chnapánaigh
laying down special control measures for a limited period of time related to infection with lumpy skin disease virus
#2087841
D’fhéadfadh bó-ainmhithe atá vacsaínithe agus táirgí ó na bó-ainmhithe sin a bheith ina riosca maidir le leathadh ionfhabhtú víreas ghalar an chraicinn chnapánaigh.
Vaccinated bovine animals and products from those bovine animals may represent a risk for the spread of infection with LSDV.
#2087845
Maidir leis an riosca go leathfaí ionfhabhtú víreas ghalar an chraicinn chnapánaigh, baineann leibhéil éagsúla riosca le tráchtearraí éagsúla.
In terms of the risk of the spread of infection with LSDV, different commodities pose different levels of risk.
#2087848
Ní féidir tarchur víreas ghalar an chraicinn chnapánaigh trí sheamhan, ubháin agus suthanna ainmhithe den speiceas buaibheach a eisiamh.
The transmission of lumpy skin disease virus through semen, ova and embryos of animals of the bovine species cannot be excluded.
#2087877
ina ndéantar vacsaíniú in aghaidh ionfhabhtú víreas ghalar an chraicinn chnapánaigh i gcomhréir le hAirteagal 3(2);
where vaccination against infection with LSDV is carried out in accordance with Article 3(2);
#2087882
ina ndéantar vacsaíniú in aghaidh ionfhabhtú víreas ghalar an chraicinn chnapánaigh i gcomhréir le hAirteagal 3(1);
where vaccination against infection with LSDV is carried out in accordance with Article 3(1);
#2087891
I gcás ina ndeimhneofar ráig d’ionfhabhtú víreas ghalar an chraicinn chnapánaigh i mbó-ainmhithe, déanfaidh an t-údarás inniúil an méid seo a leanas:
In the event of confirmation of an outbreak of infection with LSDV in bovine animals, the competent authority shall:
#2087927
COINNÍOLLACHA I nDÁIL LE GLUAISEACHTAÍ LAISTIGH DE LIMISTÉIR SHRIANTA AGUS Ó LIMISTÉIR SHRIANTA INA gCUIRTEAR I bhFEIDHM BEARTA RIALAITHE IN AGHAIDH GHALAR AN CHRAICINN CHNAPÁNAIGH
CONDITIONS FOR MOVEMENTS WITHIN AND FROM AREAS WHERE SPECIAL DISEASE CONTROL MEASURES AGAINST INFECTION WITH LUMPY SKIN DISEASE VIRUS ARE APPLIED
#2087972
rinneadh brath i leith víreas ghalar an chraicinn chnapánaigh ar an seamhan trí PCR agus bhí torthaí diúltacha ar an mbrath sin;
the semen was subjected to a LSDV detection by PCR with negative results;
#2088114
Íoscheanglais maidir le pleananna vacsaínithe in aghaidh ionfhabhtú víreas ghalar an chraicinn chnapánaigh dá dtagraítear in Airteagal 3
Minimum requirements for infection with LSDV vaccination plans as referred to in Article 3
#2088115
Beidh na pleananna vacsaínithe in aghaidh ionfhabhtú víreas ghalar an chraicinn chnapánaigh i gcomhréir leis na ceanglais theicniúla seo a leanas:
The vaccination plans against infection with LSDV shall be in accordance with the following technical requirements:
#2297724
vacsaíní in aghaidh ghalar an chraicinn chnapánaigh, a bhunaítear i gcomhréir le hAirteagal 6(5) de Rialachán (AE) Uimh. 652/2014;
vaccines against lumpy skin disease, established in accordance with Article 6(5) of Regulation (EU) No 652/2014;
#2720508
rinneadh tástáil um imoibriú slabhrúil polaiméaráise ar an seamhan, a raibh torthaí diúltacha uirthi, chun víreas ghalar an chraicinn chnapánaigh a bhrath;
the semen was subjected, with negative results, to a PCR test to detect LSD;
#2795987
maidir le bearta rialaithe galar speisialta áirithe ar feadh tréimhse theoranta a bhaineann le hionfhabhtú le víreas ghalar an chraicinn chnapánaigh i mBallstáit áirithe
concerning certain special disease control measures for a limited period of time relating to infection with lumpy skin disease virus in certain Member States
#2796026
Na Ballstáit a chuireann vacsaíniú próifiolacsach éigeandála in aghaidh ghalar an chraicinn chnapánaigh chun feidhme, áiritheoidh siad an méid seo a leanas:
Member States implementing emergency protective vaccination against lumpy skin disease shall ensure that:
#2087821
Le Rialachán Tarmligthe (AE) 2020/687 ón gCoimisiún, déantar forlíonadh ar na rialacha maidir le rialú galar i gcatagóirí A, B agus C a leagtar síos i Rialachán (AE) 2016/429, lena n-áirítear bearta rialaithe galar in aghaidh ionfhabhtú víreas ghalar an chraicinn chnapánaigh.
Commission Delegated Regulation (EU) 2020/687 supplements the rules for the control of category A, B and C diseases laid down in Regulation (EU) 2016/429, including disease control measures against infection with LSDV.
#2087869
Tá feidhm ag na bearta speisialta rialaithe galar a leagtar síos sa Rialachán seo maidir le bó-ainmhithe agus seachtháirgí agus táirgí geirmeacha a fuarthas ó na bó-ainmhithe, agus tá siad á gcur leis na bearta rialaithe galar is infheidhme maidir le cosaint, faireachas agus criosanna srianta breise a arna mbunú ag údarás inniúil Ballstáit tar éis ráig d’ionfhabhtú víreas ghalar an chraicinn chnapánaigh, i gcomhréir le hAirteagal 21(1) de Rialachán Tarmligthe (AE) 2020/687.
The special disease control measures laid down in this Regulation apply to bovine animals and by–products and germinal products obtained from such bovine animals, and are in addition to the disease control measures applicable to the protection, surveillance and further restricted zones established by the competent authority of a Member State following an outbreak of infection with LSDV, in accordance with Article 21(1) of Delegated Regulation (EU) 2020/687.
#2341868
a coinníodh ar bhunaíochtaí nach bhfuil suite i gcrios srianta a bunaíodh de bharr galar crúb agus béil a bheith ann, ionfhabhtú le víreas phlá na mbó, ionfhabhtú le víreas fhiabhras Ghleann na Claise, le pliúrainiúmóine tógálach buaibheach nó le galar an chraicinn chnapánaigh nó le galar atá ag teacht chun cinn agus a bhaineann le bó-ainmhithe;”;
were kept on establishments not situated in a restricted zone established due to the occurrence of foot-and-mouth disease, infection with rinderpest virus, infection with Rift Valley fever virus, contagious bovine pleuropneumonia or lumpy skin disease or of an emerging disease relevant for bovine animals;’;
#2795997
Ina theannta sin, maidir leis an gCróit agus an Bhoisnia agus an Heirseagaivéin, tíortha nach raibh buailte le galar an chraicinn chnapánaigh, chuir siad vacsaíniú chun feidhme mar bheart coisctheach, i bhfianaise an galar a bheith ag tarlú i dtíortha comharsanacha.
In addition, Croatia and Bosnia and Herzegovina, that were not affected by LSD, implemented vaccination as a preventive measure, in view of disease occurrence in neighbouring countries.
#2796013
Agus pleananna vacsaínithe na Bulgáire agus na Gréige le haghaidh 2023, an staid eipidéimeolaíoch a mhéid a bhaineann leis an ngalar sin san Aontas, agus an tréimhse athshlánaithe maidir le galar an chraicinn chnapánaigh a leagtar síos i Rialachán Tarmligthe (AE) 2023/361 á gcur san áireamh, beidh feidhm ag an gCinneadh seo go dtí an 31 Lúnasa 2024,
Taking into account the LSD vaccination plans of Bulgaria and Greece for 2023, the epidemiological situation as regards that disease in the Union, and the recovery period for LSD, as laid down in Delegated Regulation (EU) 2023/361, this Decision should apply until 31 August 2024,
#2087819
Liostaítear ionfhabhtú víreas ghalar an chraicinn chnapánaigh in Iarscríbhinn II a ghabhann le Rialachán (AE) 2016/429, agus dá réir sin is galar liostaithe é chun críocha an Rialacháin sin, agus tá sé faoi réir na rialacha maidir le galair a chosc agus a rialú a leagtar síos ann.
Infection with lumpy skin disease virus is listed in Annex II to Regulation (EU) 2016/429, and accordingly it is a listed disease for the purposes of that Regulation, and it is subject to the disease prevention and control rules laid down therein.
#2087826
Ó 2017 i leith, níor tuairiscíodh aon ráig d’ionfhabhtú víreas ghalar an chraicinn chnapánaigh san Eoraip, ach tá an galar sin fós in Anatóil na Tuirce agus sa Rúis, agus in Oirthear na hÁise, rud a dhéanann difear don Bhanglaidéis, don tSín agus don India.
Since 2017, no outbreaks of infection with LSDV have been reported in Europe, but that disease is still present in Anatolia, Turkey, and in Russia, as well as in eastern Asia affecting Bangladesh, China and India.